May 6, 2022 · Intestinal mucosal inflammation and epithelial barrier dysfunction have been implicated as pathological factors in inflammatory bowel disease (IBD). An emerging area of IBD research focuses on probiotics. The probiotic Escherichia coli Nissle 1917 (EcN) is an excellent choice for engineering therapeutic microbes. Elafin is an endogenous specific inhibitor of neutrophil elastase (NE) and It is protective against many forms of bad E. coli and other bad bacteria that may attack the gut. Nissle 1917 is a natural colonizer. When introduced into the gut it rapidly regulates bowel movements, stimulates defence systems, reduces gut inflammation, repairs leaky gut conditions, displaces and kills many forms of bad bacteria and improves Sep 15, 2022 · Towards that goal, we engineered a novel system in which the probiotic bacterial strain E. coli Nissle 1917 (EcN) is used to express and display VHHs at high density on its surface. By demonstrating the ability of these engineered EcN to bind to pathogens, we provide a first step toward using such probiotics as a cheap, simple, and effective Jan 13, 2008 · 4, 5 Approximately 50,000 different E. coli strains occur naturally and in 1917, during WW I, the German physiologist, microbiologist, and physician Alfred Nissle (1874–1965) managed to isolate a particularly high-grade E. coli strain from the feces of an officer who did not succumb to any of the intestinal disorders then highly prevalent in Aug 9, 2021 · Escherichia coli Nissle 1917 (EcN) is a commonly used probiotic in clinical practice. Its facultative anaerobic property drives it to selectively colonize in the hypoxic area of the tumor for survival and reproduction. EcN can be engineered as a bacteria-based microrobot for molecular imaging, drug delivery, and gene delivery. Jun 16, 2023 · Engineering E. coli Nissle 1917 to reset the balance of bile salts in CDI, by converting the conjugated bile salts to the unconjugated forms in the intestine, substantially reduced CDI in mice 135. E.coli Nissle 1917 (DSM 6601)(EcN) is the active compound of a microbial drug for use in humans (Mutaflor TM ), commercially available in Central Europe for nearly 90 years. This E. coli strain of Omega-3 fatty acids, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have beneficial effects on human health. The probiotic bacterium Escherichia coli Nissle is unable to produce either EPA or DHA. Escherichia coli Nissle was transformed with the pfBS-PS plasmid carrying the EPA/DHA gene cluster, previously isolated from a Probiotics such as Escherichia coli Nissle 1917 and lactic acid bacteria are currently used to, or have been evaluated for use to, prevent or treat a range of intestinal maladies including inflammatory bowel disease, constipation, and colon cancer. Engineering these natural probiotics to produce immunomodulatory molecules may help to further Nov 9, 2022 · Nattokinase with excellent anti-thrombotic, anti-inflammatory, anti-tumor, and anti-hypertension properties has been used in the development of several healthcare products in many countries. The probiotic Escherichia coli Nissle 1917 (EcN) with anti-inflammatory effect is commonly used to treat inflammatory bowel disease. To determine whether nattokinase could enhance the therapeutic efficacy hMc3.